Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) – Pipeline Review, H2 2016’, provides in depth analysis on Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted pipeline therapeutics.

The report provides comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects

The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Allergan Plc

Amgen Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

Vertex Pharmaceuticals Incorporated

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) Overview 7

Therapeutics Development 8

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Products under Development by Stage of Development 8

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Products under Development by Therapy Area 9

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Products under Development by Indication 10

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Products under Development by Companies 13

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development 22

Allergan Plc 22

Amgen Inc. 23

Bristol-Myers Squibb Company 24

Eli Lilly and Company 25

Merck & Co., Inc. 26

Teva Pharmaceutical Industries Ltd. 27

Vertex Pharmaceuticals Incorporated 28

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles 29

AA-71 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

AFAP-3 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

AGN-241689 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

erenumab - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

MK-8031 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

MK-8825 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecule to Antagonize CALCRL for Migraine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Inhibit CGRP for Migraine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Agonize CLR and RAMP Receptors for Pre-Eclampsia - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ubrogepant - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Projects 44

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products 45

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Featured News & Press Releases 46

Jun 08, 2016: Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine 46

Jun 19, 2015: Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine 46

May 15, 2015: Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine 47

May 11, 2015: Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society 48

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Allergan Plc, H2 2016 22

Pipeline by Amgen Inc., H2 2016 23

Pipeline by Bristol-Myers Squibb Company, H2 2016 24

Pipeline by Eli Lilly and Company, H2 2016 25

Pipeline by Merck & Co., Inc., H2 2016 26

Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 27

Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 28

Dormant Projects, H2 2016 44

Discontinued Products, H2 2016 45

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports